740 Heinz Avenue
About Aduro Biotech
Aduro Biotech, Inc. is a Berkeley, California-based immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases.
Aduro's three proprietary technology platforms, Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies, are designed to harness the body's natural immune system. Our extensive pipeline of product candidates derived from these platforms are currently being investigated in a variety of cancer indications and have the potential to expand into autoimmune and infectious diseases.
Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric/esophageal, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor.
Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas.
Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.
Learn more at www.aduro.com.
Aduro Biotech. Pioneering Immunotherapy. Transforming Lives.
123 articles with Aduro Biotech
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
10/2/2018Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Preliminary Phase 1 data for novel STING pathway activator ADU-S100 (MIW815) accepted for presentation
Aduro Biotech, Inc. today announced that four separate abstracts from its research and development portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from November 7-11, 2018.
Ms. Lew, who previously served as the company’s senior vice president of finance, will oversee the company’s global finance operations, including accounting, planning, and investor relations functions.
Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent
The STING pathway plays a central role in the activation of an immune response and in the regulation of inflammation, and therefore, has been implicated in numerous diseases such as cancer and autoimmune disorders.
Aduro Biotech Announces the Initiation of a Phase I/II Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma
The study is designed to evaluate the safety and activity of BION-1301, a humanized anti-APRIL antibody, for adults with relapsed or refractory multiple myeloma.
The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.
The webcast will be archived and available for replay for one month following the event.
Poster #335 to be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer.
Net loss for the third quarter of 2017 was $24.5 million, or $0.33 per share.
Aduro Biotech Announces Presentation of Phase I Data for LADD-based Immunotherapy at World Confer...
10/17/2017The Phase 1 first-in-human, open label dose-finding trial included nine patients with advanced stage relapsed or refractory non-small cell lung cancer.
Aduro Biotech Announces First Patient Dosed In Phase I Clinical Trial Of Personalized Immunotherapy Pladd Based On Proprietary Neoantigen Technology
Aduro Biotech Announces Advancement Of ADU-S100 Into Global Combination Trial With PDR001 For The Treatment Of Solid Tumors And Lymphomas
Aduro Biotech Announces Andrea Van Elsas, Ph.D., To Be Named Chief Scientific Officer Effective September 1, 2017
Aduro Biotech Announces Milestone Achieved Relating To Collaboration With Merck & Co. For Development Of Anti-CD27 Antibody For The Treatment Of Cancer
Aduro Biotech Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA® (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma
Aduro Biotech Announces FDA Clearance Of Investigational New Drug Application To Evaluate The Combination Of ADU-S100 With PDR001 For The Treatment Of Solid Tumors And Lymphomas